RT Journal Article SR Electronic T1 Gray matter networks associated with cognitive deficit in ADHD across adolescence and adulthood JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.22.20059808 DO 10.1101/2020.04.22.20059808 A1 Jingyu Liu A1 Kuaikuai Duan A1 Wenhao Jiang A1 Kelly Rootes-Murdy A1 Gido Schoenmacker A1 Jan K. Buitelaar A1 Martine Hoogman A1 Jaap Oosterlaan A1 Pieter J. Hoekstra A1 Dirk J. Heslenfeld A1 Catharina A. Hartman A1 Vince D. Calhoun A1 Alejandro Arias-Vasquez A1 Jessica A. Turner YR 2020 UL http://medrxiv.org/content/early/2020/04/24/2020.04.22.20059808.abstract AB Attention-deficit/hyperactivity disorder (ADHD) is a childhood-onset neuropsychiatric disorder, and its existence in adulthood is well established. Beyond symptoms of inattention and hyperactivity/impulsivity, patients commonly present with impairments in cognition. How neuronal underpinnings of symptoms and cognitive deficits differ across adolescence and adulthood is not clear. In this cross sectional study, we investigated gray matter of two cohorts, 486 adults and 508 adolescents, each including participants with ADHD and healthy controls. Independent component analysis was applied to the gray matter of each cohort, separately, to extract cohort specific networks. Then, we identified gray matter networks associated with symptoms, working memory and/or diagnosis in each cohort, and projected them onto the other cohort for comparison. Two components in the inferior, middle/superior frontal regions identified in adults and one component in the insula and inferior frontal region identified in adolescents were significantly associated with working memory deficits in both cohorts. One component in bilateral cerebellar tonsil and culmen identified in adults and one component in left cerebellar region identified in adolescents were significantly associated with inattentive symptoms in both cohorts. All these components presented significant or nominal level of gray matter reduction for ADHD patients in adolescents, but only one showed nominal reduction for patients in adults. Our findings suggest gray matter reduction may not be a sensitive marker for persist ADHD. However, the patterns of certain brain regions are associated with deficits in working memory or attention persistently from childhood into adulthood, which might help understand the mechanism of disease persistence.Competing Interest StatementDr. Buitelaar has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire, Roche, Medice, Novartis, and Servier. He has received research support from Roche and Vifor. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. The other authors report no financial relationship and competing interests.Funding StatementWe would like to thank the supporting agency of the study, the National Institutes of Health, through the grant 1R01MH106655. This study makes use of data from the Dutch NeuroIMAGE project and the Dutch site of IMpACT (International Multi-center persistent ADHD Collaboration) project. The NeuroIMAGE project was supported by NWO Large Investment grant 1750102007010 (Dr Buitelaar), ZonMW Addiction: Risk Behaviour and Dependency Grant 60-60600-97-193 (Dr Buitelaar), NWO Brain & Cognition: an Integrative Approach grant 433-09-242 (Dr Buitelaar), NWO National Initiative Brain & Cognition 056-13-015 (Dr Buitelaar), the EU FP7 grants TACTICS (278948), IMAGEMEND (602450), MATRICS (603016) and AGGRESSOTYPE (602805), EU IMI grant EU-AIMS (115300) and EU H2020 grant Eat2beNICE (728018) and grants from Radboudumc, University Medical Center Groningen, Accare, and VU University Amsterdam. The Dutch IMpACT study acknowledges the following sources of support: The Netherlands Organization for Scientific Research (NWO), i.e. the NWO Brain & Cognition Excellence Program (grant 433-09-229) and the Vici Innovation Program (grant 016-130-669 to BF). Additional support was received from the European Community’s Seventh Framework Programme (FP7/2007 – 2013) under grant agreements n° 602805 (Aggressotype), n° 602450 (IMAGEMEND), and n° 278948 (TACTICS) as well as from the European Community’s Horizon 2020 Programme (H2020/2014 – 2020) under grant agreements n° 643051 (MiND), Eat2beNICE (728018) and n° 667302 (CoCA). The work was also supported by grants for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership, and by the ECNP Network ADHD across the Lifespan. The authors also thank all participants to these two projects.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo new data were collected in this study.